LCTX EBITDA Margin

Lineage Cell Therapeutics, Inc. Common Stock · EBITDA Margin

LCTX logo

LCTX EBITDA Margin

Latest reported-280.10%
LCTX TTM EBITDA Margin (-333.33% → -280.10%)
High-resolution chart · PNG

LCTX ebitda margin history

Trailing twelve months (TTM). Each value covers four complete reported quarters.

Lineage Cell Therapeutics, Inc. Common Stock EBITDA Margin — Trailing twelve months (TTM)
Period endingEBITDA Margin
-280.104%
-291.9413%
-292.1407%
-382.9604%
-134.7535%
-162.9068%
-189.2094%
-222.6517%
-380.4559%
-286.605%
-252.5433%
-276.3338%
-215.1273%
-204.2356%
-170.6114%
-339.7876%
-385.8786%
-544.6267%
-1,231.8789%
-829.207%
-1,880.1127%
-2,716%
-3,157.5679%
-1,737.3176%
-2,007.9909%
-2,088.5324%
-2,427.3342%
-4,799.1432%
-4,756.9444%
-3,222.377%
-2,671.6102%
-2,043.1092%
-1,797.9136%
-2,093.9597%
-2,084.8214%
-1,972.943%
-2,047.4843%
-2,097.4422%
-2,420.1786%
-3,135.4443%
-2,844.029%
-2,724.5593%
-2,348.0869%
-2,220.9907%
-2,294.2836%
-2,388.9171%
-2,356.5821%
-1,508.9149%
-1,463.5067%
-1,289.6597%
-1,208.6842%
-1,445.3492%
-1,029.1895%
-795.5507%
-695.4523%
-485.4144%
-432.0754%
-435.3904%
-378.8644%
-355.5462%
-352.4769%
-301.635%
-242.4344%
-131.8378%
-176.4287%
-150.1705%
-165.4304%
-402.9793%
-268.9685%
-256.8153%
-206.0857%
-151.9867%
-118.1273%
-88.7875%
-114.7299%
-263.0304%
-254.2134%
-298.6162%
-295.476%
-195.2644%
-230.6819%
-183.3705%
-222.768%
-245.7551%
-267.79%
-288.6442%
-133.6417%
-60.4865%
-27.2309%
-8.3795%
-158.017%
-249.5723%
-229.8184%
-314.9892%
-376.342%
-461.6052%
-1,018.1008%
-1,496.5329%
-2,076.8439%
-2,629.1218%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.